immunitoAI Private Limited

Based in India, immunitoAI focuses on creating AI-generated antibody therapeutics, employing a unique platform for efficient drug design that targets proteins with tailored properties. immunitoAI Private Limited was founded in 2020 in Bangalore, India, by Aridni Shah and Trisha Chatterjee. The company operates in the biotech sector, specifically dedicated to antibody therapeutic solutions. In November 2025, immunitoAI Private Limited raised USD 6.

1 million in series A funding led by an individual investor, with participation from new investors 3one4Capital Advisors and AC Ventures. Returning investors pi Ventures, Anicut Capital, JITO Incubation & Innovation Foundation, JJ Family Office, and LVX also participated in the round. Their patented AI platform facilitates in silico antibody design that targets any protein and incorporates innovative biological validation methods. The company's primary focus is on Drug-First Antibodies, which ensures that therapeutic drugs are engineered with specific characteristics right from the start, streamlining the development process.

They primarily serve pharmaceutical companies and research institutions, and their market presence includes North America, Europe, and Asia, meeting the increasing demand for advanced therapeutic options. In 2023, immunitoAI reported zero revenue with an EBITDA of INR -348,301. 1. The company's revenue model is primarily centered on B2B transactions where AI-based therapeutic solutions are sold directly to pharmaceutical and biotech firms.

They engage in tailored partnerships for antibody design, facilitating licensing agreements, and providing subscription access to their platform for ongoing research. Following the SEED round raised in September 2021, immunitoAI plans to utilize the capital for product development and to forge industry partnerships. The company will use the funding to develop antibodies for targeted diseases.